MedTrace Logo

Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation

NCT01038687 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-09-04

Study results available
· View outcomes & findings →

Summary

This is a single-center, randomized, parallel group, double-blind, placebo-controlled, dose response, pharmacodynamic and pharmacokinetic study evaluating the effects of A3309 on gastric, intestinal and colonic transit in patients with functional constipation.

Conditions

  • Functional Constipation

Interventions

DRUG

A3309

A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets

DRUG

placebo

placebo

Sponsors & Collaborators

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • Michael Camilleri, MD

    lead OTHER

Principal Investigators

  • Michael Camilleri, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01038687 on ClinicalTrials.gov